Skip to content

Author

C. A. Andra

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Unveiling Cardiac Amyloidosis: A Case Report Exploring The Role of Multimodal Imaging

Background: Cardiac Amyloidosis (CA) is a condition caused by the deposition of amyloid fibrils in the heart. The diagnosis of CA can be challenging and requires a high index of suspicion. Multimodality imaging, including echocardiography and Cardiac Magnetic Resonance (CMR), plays a crucial role in the diagnosis, eval...

Yosua Cristo Reynaldo Napitupulu, H. A. P. Lubis, C. A. Andra et al. · 0 citations
Open access Oct 2026

LEFT ATRIAL RESERVOIR STRAIN AS A NON-INVASIVE MARKER OF CORONARY ARTERY DISEASE SEVERITY IN PRESERVED-EF PATIENTS

In preserved-EF patients, LARS decreases with increasing CAD severity and differentiates CAD burden better than conventional LV structural and functional parameters, supporting its potential utility as a non-invasive marker of CAD severity.

G. Justisia, A. P. Ketaren, C. A. Andra · 0 citations
Open access Sep 2026

Incremental Prognostic Value of the Triglyceride–Glucose Index Beyond the GRACE Score for Predicting 30-Day Major Adverse Cardiovascular Events in non ST-elevation myocardial infarction Patients Undergoing Percutaneous Coronary Intervention

Background: The Global Registry of Acute Coronary Events (GRACE) score is widely used for risk stratification in patients with non–ST-elevation myocardial infarction (NSTEMI). However, it does not account for metabolic factors such as insulin resistance, which may contribute to residual cardiovascular risk. The triglyc...

F. Zahra, C. A. Andra, A. H. Raynaldo et al. · 0 citations
Open access Aug 2026

Characteristics of Heart Failure Patients with Reduced Left Ventricular Ejection Fraction (HFrEF) Using Angiotensin Receptor-Neprilysin Inhibitors (ARNI) Compared to Angiotensin Converting Enzyme-Inhibitor (ACE-I)/Angiotensin Receptor Blocker (ARB) Therap

BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) remains a major cause of cardiovascular morbidity. While guideline-directed medical therapy, including Angiotensin Receptor Neprylisin Inhibitor (ARNI) dan Angiotensin Converting Enzyme-Inhibitor (ACE-I)/Angiotensin Receptor Blocker (ARB), is well-establi...

Grace Nikensari, C. A. Andra, Ali Nafiah Nasution et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.